Anocca AB

SÖDERTÄLJE, Sweden, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Anocca AB, a leading T cell receptor-engineered T cell (TCR-T) cellular therapeutics company, announces it will present its novel platform approach to therapeutic TCR discovery and preclinical data for its lead TCR-T cell therapy product at the European Society of Medical Oncology (ESMO) Congress 2024. Category: Investigational ImmunologyPoster title: Preclinical development of TCR-modified T-cell therapies against mutated KRAS Date and time: 9am-5pm local time on Saturday 14 SeptemberLocation: Hall 6, Fira Barcelona Gran Via, Barcelona, SpainLink: https://tinyurl.com/4n67775y The poster introduces Anocca’s programmable cellular technology platform that systematically recreates human T-cell biology to map T-cell targets and build TCR libraries for the generation of validated therapeutic TCRs, and describes the preclinical development of its lead therapeutic TCR-T product targeting KRAS-G12V that is being progressed into planned clinical trials. KRAS is the most frequently mutated oncogene and associated with highly fatal cancers of the pancreas, lung and colon. Due to its intrinsic properties, effective targeting strategies have historically been elusive, presenting significant unmet need. Hugh Salter, Chief Scientific Officer at Anocca, and presenter of the poster, added, "We are excited to present our technology platform and the details of our lead TCR-T product at ESMO. Our research demonstrates that TCR-T cell therapies offer a precise route, via autologous modification of patient CD8 cells, to directly address foundational driver events in solid tumours.” Members of the company’s management team, including CSO Hugh Salter, CMO Zahid Bashir, Clinical Science Lead Rehab Alnabhan, and Director of Clinical Operations Sheila Forsman, will be available for meetings at ESMO. About AnoccaAnocca is a fully integrated biopharmaceutical company developing libraries of T cell receptor-engineered T cell (TCR-T) therapies to redefine the treatment of solid tumours and other difficult to treat diseases, including infectious and autoimmune diseases. Its proprietary technologies have been designed to vastly expand TCR-T cell therapy development, allowing the systematic generation of treatments for the broadest patient populations that equip the immune system against the most difficult to treat solid tumours. Anocca operates an advanced research and development infrastructure, underpinned by a custom software ecosystem and in-house clinical manufacturing and process development facilities. Its unique discovery platform uses programmable human cells to recreate and manipulate T cell immunity. Follow Anocca on LinkedIn and visit our website Media Inquiries Anocca ABwww.anocca.com/contact Scius Communications (for Anocca AB)Katja StoutTel: +44 7789 435 990katja@sciuscommunications.com Daniel GoochTel: +44 7747 875 479daniel@sciuscommunications.com

Co-developing immune-evasive allogeneic TCR-iPS-T-cell therapies for the treatment of solid tumors SÖDERTÄLJE, Sweden and SAN FRANCISCO and KYOTO, Japan, May 30, 2024 (GLOBE NEWSWIRE) -- Anocca AB (Anocca), a leading T-cell receptor-engineered T-cell (TCR-T) therapeutics company, and Shinobi Therapeutics (Shinobi), developer of immune-evasive induced pluripotent stem cell (iPSC)-derived CD8 αβT-cell therapies (iPS-T), today announced a strategic partnership to use Shinobi’s proprietary immune evasive iPS-T cell platform with novel candidate TCRs, discovered and validated by Anocca, to develop a new class of off-the-shelf allogeneic TCR engineered iPS-T-cell therapies (TCR-iPS-T) for solid tumors. “Anocca has made tremendous progress using our unique technology platform to systematically map cancer targets and build potent and highly specific TCR libraries to deliver personalized TCR-T treatments. As we prepare to progress our first gene-edited autologous TCR-T product into the clinic, we are excited to partner with Shinobi and work together to develop innovative off-the-shelf TCR-T cell therapies,” said Anocca’s CEO and co-founder, Reagan Jarvis. “Shinobi’s Katana platform has the potential to offer treatment options for most cancer patients when combined with Anocca’s ability to systematically unlock the largely unexploited landscape of TCR-T targets.” “Combining Shinobi’s immune evasive iPS-T cell platform with Anocca’s world-class TCR discovery platform will accelerate our mission of building a comprehensive pipeline of TCR and CAR-targeted off-the-shelf T-cell therapies,” said Dan Kemp, Shinobi’s CEO. “This is an ideal partnership between two emerging biotechs where the alignment of our technologies could realize a shared goal of making transformative TCR-iPS-T cell therapies and making them accessible to cancer patients on a global scale.” Shinobi’s ‘Katana’ technology specifically enables the efficient introduction of antigen-targeting TCR and/or CAR constructs into its immune evasive iPS-T cells in a plug-and-play manner. Anocca has developed a unique deep-tech discovery platform that uses programmable human cells to recreate and manipulate T-cell immunity and deliver libraries of highly specific, clinically deployable TCR candidates for the treatment of solid cancers. In this joint program, Shinobi and Anocca will work together to produce TCR engineered CD8 αβiPS-T-cells against validated cancer targets and deliver pre-clinical proof of concept. A successful outcome will pave the way for the development of novel off-the-shelf treatments in solid tumor indications for the broadest patient populations. Notes to editors About Shinobi Therapeutics Shinobi Therapeutics is a biotechnology company developing a new class of off-the-shelf immune evasive iPSC-derived cell therapies. Based on the research of scientific co-founders Shin Kaneko, M.D., Ph.D., at Kyoto University and Tobias Deuse, M.D., at University of California, San Francisco, Shinobi has created a new allogeneic CD8 αβiPS-T-cell platform that demonstrates comprehensive immune evasion from all arms of the immune system. For more information, please visit . About Anocca Anocca is a biotechnology company developing libraries of T-cell receptor-engineered T-cell (TCR-T) therapies to redefine the treatment of solid tumors. Its proprietary technologies have been designed to vastly expand TCR-T development, allowing the systematic generation of treatments for the broadest patient populations that equip the immune system against the most difficult to treat solid tumors. Anocca operates an advanced research and development infrastructure, underpinned by AnoccaOS, a custom software ecosystem, and in-house clinical manufacturing and process development facilities. Its unique discovery platform uses programmable human cells to recreate and manipulate T-cell immunity. Follow Anocca on LinkedIn and visit . About Autologous and Allogeneic Cell Therapy Autologous cell therapy uses immune cells derived from a patient that are engineered and transferred back to the same patient, thus avoiding rejection by the patients’ own immune system. The current gold standard, autologous manufacture of cell therapy limits the type of patients that can be treated, as the patient’s own immune cells are used as the source of T-cells to modify. Allogeneic cell therapy, utilizing iPS cell-derived immune cells, is an attractive alternative as production of allogeneic immune cells can be scaled up and made available off-the-shelf, without the need to modify a patient’s immune cells. However, a major challenge in current allogeneic approaches is allo-rejection, as the patients' immune systems reject donor-derived and engineered cells as foreign invaders. Media Inquiries Anocca AB Mark Farmery, CDO media@anocca.com Scius Communications (for Anocca AB) Katja Stout Tel: +44 7789 435 990 katja@sciuscommunications.com Daniel Gooch Tel: +44 7747 875 479 daniel@sciuscommunications.com Shinobi Therapeutics Molly Cole molly.cole@shinobitx.com

EmendoBio’s technology will aid Anocca in delivering tailored therapies to patients more rapidly. Credit: Natali _ Mis / Shutterstock.com. Swedish biotech company Anocca has entered a non-exclusive licensing agreement with EmendoBio to use the latter’s OMNI-A4 nuclease, a gene editing technology [that cleaves chains of nucleotides in nucleic acids into smaller units]. This strategic move is set to expedite developing and manufacturing Anocca’s pipeline of T cell receptor-engineered T cell (TCR-T) therapies, targeting difficult-to-treat solid cancers. The latest development comes after Anocca received good manufacturing practice compliance certification and a manufacturing licence from regulators in Sweden for its cell therapy production facility. Anocca CEO and co-founder Reagan Jarvis stated: “Integrating EmendoBio’s nuclease into our manufacturing process supports Anocca’s aim of generating the highest-quality cell therapy products. “This next-generation gene editing system provides the precision and efficiency needed to scale out production of our growing libraries of TCR-T products in a high-precision manufacturing process. See Also: Eli Lilly-backed Zephyr AI secures $111m for precision medicine tech Almirall to license Eloxx’s ZKN-013 for rare skin conditions “We are excited to work with EmendoBio to develop gene-edited TCR-T cell therapies as we prepare for our first clinical programme targeting the KRAS driver mutation in a hard-to-treat solid cancer.” EmendoBio’s technology is expected to significantly enhance Anocca’s manufacturing expertise. It will also aid the company in delivering tailored therapies to patients more rapidly, focusing on the genetic causes of hard-to-treat cancer types. The licensed gene editing technology is part of EmendoBio’s nuclease suite designed for high activity and specificity within cell therapy applications. EmendoBio director Dr Ei Yamada stated: “This non-exclusive licensing agreement marks a significant milestone in the field of T cell therapy. “Together with Anocca, we are embracing the shared vision of harnessing the potential of gene editing and cellular therapies to make a profound impact on patient outcomes. Our combined expertise will unlock novel avenues for therapeutic development and push the boundaries of what’s possible in advanced medicine.” In May 2023, Anocca secured Skr400m ($38.9m) in an equity financing round to develop next-generation cell therapies for cancer on an industrial scale. AMF and Mellby Gård led the funding round. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content. Free Whitepaper Cell and gene therapies: Pipe dream to pipeline The cell and gene industry is gaining momentum, with a new wave of therapies promising to transform the way doctors treat, and even cure, disease. In this report, Cytiva and GlobalData have collaborated to explore the rise of the cell and gene therapy industries, the current state of the market, present and future opportunities for advancement, and the challenges that lie ahead. By Cytiva Thematic By downloading this case study, you acknowledge that GlobalData may share your information with Cytiva Thematic and that your personal data will be used as described in their Privacy Policy